Patients using antihistamines show a reduction in the skeletal progression of osteoarthritis of the knee

Source / Disclosures


Bihlet AR, et al. Antihistamine use and the structural progression of knee OA: a post hoc analysis of two phase III clinical trials. Presented at: EULAR 2022 Conference; June 1-4, 2022 (virtual meeting).

Bihlet states that she is an employee and shareholder of NBCD A/S.

We were unable to process your request. Please try again later. If this issue still occurs, please contact

Patients with knee osteoarthritis who receive antihistamines show less progression of skeletal disease, compared to those who did not take antihistamines, over a two-year period, according to data presented at the EULAR 2022 conference.

“Because one of the primary effects of antihistamines is indeed the inhibition of mast cell degeneration, we hypothesized that for people with osteoporosis, antihistamine use is associated with a lower risk of skeletal progression,” Asger Rainstrup BehletAnd the Master’sof NBCD A/S, a biotechnology company specializing in knee osteoarthritis based in Herlev, Denmark, told attendees.

knee inflammation

Patients with knee osteoarthritis who received antihistamines showed less progression of skeletal disease, compared to those who did not take antihistamines, over a two-year period, according to the data. Source: Adobe Stock

To investigate the effect of antihistamines on skeletal progression in OA, Pehlt and colleagues conducted a post-hoc analysis of 2-phase 3 trials analyzing the use of oral salmonid calcitonin in the knee. The trials investigated the effects over a two-year period. The primary outcome measure in both studies was skeletal progression, defined as “the change in the minimum width of the joint space measured using X-ray imaging from baseline to year 2,” Behlit said. Researchers have reported the use of antihistamines as any drug encoded by R06A.

Pehlet and colleagues evaluated outcomes in patients who used antihistamines compared to patients who did not. In addition, patients were placed in groups based on periods of antihistamine use, defined as 1–49 days, 50–299 days and >300 days. Analysis was performed using the ANCOVA system, with adjustments for age, gender, body mass index, and baseline joint space width.

The analysis included a total of 2,206 patients. Of these, 1,485 patients completed the trial. There were 1,327 patients who did not report antihistamine use during the study duration, and 158 who reported any duration of use. In all, there were 74 patients in the 1-49-day group, 21 patients in the 50-299-day group and 63 patients in the 300-day-plus group. According to the researchers, the mean change in joint space width among non-histaminers was -0.32 mm (95% confidence interval, -0.36 to -0.29), compared to -0.19 mm (95% confidence interval, -0.29 to -0.08). ) in patients who reported using antihistamines for any duration.

“In a subsequent analysis of these two OA clinical trials, participants taking antihistamines underwent lower skeletal development compared to those who did not take antihistamines during the two-year study period,” Behlet said. “The observed reduction in skeletal progression appears to be related to the duration of antihistamine treatment.”

2022-06-07 09:34:12

Leave a Comment

Your email address will not be published. Required fields are marked *